1,206 results on '"Schetelig, Johannes"'
Search Results
102. Simultaneous determination of clofarabine and cytarabine in human plasma by LC–MS/MS
103. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
104. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD
105. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients with Intermediate-Risk Acute Myeloid Leukemia : A Randomized Clinical Trial
106. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
107. Reduced-Intensity Conditioning Combined with 188Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion
108. Mutated IKZF1is an independent marker of adverse risk in acute myeloid leukemia
109. Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societé Française de Greffe de Moelle et Therapie Cellulaire
110. Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party
111. Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany
112. Post‐COVID‐19 condition in the German working population: A cross‐sectional study of 200,000 registered stem cell donors
113. Fascia training in patients undergoing allogeneic hematopoietic cell transplantation—a pilot study
114. Potential of TCR sequencing in graft-versus-host disease
115. Reanalysis of unclear CMV status results from buccal swab samples of potential stem cell donors is an efficient donor registry strategy
116. Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
117. Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
118. In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial
119. Fast-Track Measurable Residual Disease Detection By Multiparametric Flow Cytometry in Acute Myeloid Leukemia before Allogeneic Hematopoietic Cell Transplantation
120. Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT
121. Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT
122. Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
123. Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
124. Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
125. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy
126. Perturbations of mesenchymal stromal cells after allogeneic hematopoietic cell transplantation predispose for bone marrow graft-versus-host-disease
127. Breast cancer mortality of older patients with and without recurrence analysed by novel multi-state models
128. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
129. Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with intermediate-risk - results of the randomized ETAL-1 trial
130. Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
131. Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany.
132. Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
133. Large case-control study indicates no association of KIRgenotype and risk of developing acute myeloid leukemia
134. Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
135. Multiple imputation for cause-specific Cox models: Assessing methods for estimation and prediction
136. NPM1 and DNMT3A mutations are associated with distinct blast immunophenotype in acute myeloid leukemia
137. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML
138. Reconstitution of Interleukin-17–Producing T Helper Cells after Allogeneic Hematopoietic Cell Transplantation
139. Point Mutations in the FLT3-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant KMT2A-PTD
140. Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse
141. sj-pdf-7-smm-10.1177_09622802221074156 - Supplemental material for Integrating relative survival in multi-state models—a non-parametric approach
142. sj-pdf-1-smm-10.1177_09622802221102623 - Supplemental material for Multiple imputation for cause-specific Cox models: Assessing methods for estimation and prediction
143. sj-docx-1-tah-10.1177_20406207221115005 – Supplemental material for Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation
144. Additional file 1 of Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
145. Additional file 1 of Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
146. sj-docx-1-tah-10.1177_20406207221090882 – Supplemental material for Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors
147. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial
148. Post‐COVID‐19 condition in the German working population: A cross‐sectional study of 200,000 registered stem cell donors.
149. Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and −5/5q−
150. Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.